A single subcutaneous dose led to a 4-point or greater itch reduction in 82% of patients with chronic pruritus at week 12 vs 22% with placebo, Attovia reported.
|Articles|August 1, 2003
Ms.Codit
Author(s)Inga Ellzey
Q: As HIPAA moves ahead at full speed, it has brought my attention to many other issues in our practice ?? among them chart audits. We have four physicians and two physician assistants in our practice. I plan to perform chart audits personally but don't know where to start. How do I get started?
Advertisement
Advertisement
Related to this article
At a Dermatology Times Case-Based Roundtable event, Carolyn Goh, MD, led clinicians through a discussion of severity scoring, patient-reported outcomes, CYP2C9 testing, and long-term monitoring across 3 alopecia areata cases.
The AADA warns that dermatologists could face a 6% Medicare payment reduction in 2027 despite CMS revisions to modifier 25 policies.
Pediatric dermatologists outline how to evaluate suspected topical steroid withdrawal, exclude mimics, and preserve family trust in eczema care.
Diego Ruiz Dasilva, MD, and Lindsey Finklea, MD, discuss the burden of chronic inducible urticaria and phase 3 remIND findings for remibrutinib.
Doral Fredericks, PharmD, MBA, discusses how life stages, mental health, and reproductive concerns can shape dermatologic care for women.
Gaurav Singh, MD, MPH, explains how pharmacokinetics, trial design, and real-world tolerability set sonidegib apart from vismodegib in locally advanced basal cell carcinoma and when to start systemic therapy earlier.
Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.
Advertisement
Advertisement
Trending on Dermatology Times
1
AADA Warns of 6% Medicare Payment Cut for Dermatologists in 2027
2
Why Hedgehog Inhibitors Are Not Interchangeable in Locally Advanced BCC
3
ATTO-1310 Reduces Itch at Week 12 in Chronic Pruritus and Atopic Dermatitis
4
Bone Alkaline Phosphatase and Growth in Pediatric Atopic Dermatitis
5